On Saturday, people in parts of the United States, Canada, the Caribbean, Europe, Russia and Africa will get to experience a ...

Pain in your eyes is unlikely to be a symptom of solar retinopathy, since the retina doesn’t have any pain receptors. The ...

The EMA’s Committee for Medicinal Products for Human Use said that a phase 3 study in children aged 3-14 years demonstrated ...

The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.

Integrated nicotine replacement and behavioral support at opioid agonist treatment clinics helped opioid-dependent patients reduce cigarette use.

IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Microdosing psychedelics like LSD and psilocybin shows potential for enhancing mental health, creativity, and cognitive ...

Richard Paolone, CEO of Entero, commented, "After completion of our internal review, we determined that executing the Rescission Agreement was the best option for Entero and our shareholders.

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") ...

These cells are often found in heterogeneous tumors and include cancer stem-like cells (CSCs), cells undergoing epithelial-to ...